Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 13/20 | 0.55 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 5/20 | 0.40 |
| ▸ | QRFPR | Q96P65 | 3/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.39 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.39 |
| ▸ | AHR | P35869 | 1/20 | 0.38 |
| ▸ | F11 | P03951 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1173939 | 0.93 | HDAC6 (0.55) | HDAC6BRD4QRFPRKCNH2CYP2D6 | |
| SCHEMBL12883422 | 0.81 | HDAC6 (0.60) | HDAC6KDM1AQRFPRKCNH2CYP2D6 | |
| SCHEMBL7795333 | 0.81 | HDAC6 (0.59) | HDAC6KDM1AQRFPRKCNH2CYP2D6 | |
| SCHEMBL12883087 | 0.74 | HDAC6 (0.60) | HDAC6QRFPRKCNH2CYP2D6KCNE1 | |
| SCHEMBL7796723 | 0.74 | HDAC6 (0.59) | HDAC6BRD4QRFPRKCNH2CYP2D6 | |
| SCHEMBL1173979 | 0.73 | HDAC6 (0.66) | HDAC6KDM1AHDAC3HDAC1HDAC8 | |
| SCHEMBL1174737 | 0.72 | HDAC6 (1.00) | HDAC6KDM1AHDAC3HDAC1HDAC8 | |
| SCHEMBL16220611 | 0.72 | NAMPT (0.50) | F11 | |
| SCHEMBL7795389 | 0.70 | HDAC6 (0.74) | HDAC6KDM1AHDAC3HDAC1HDAC8 | |
| SCHEMBL12868309 | 0.69 | THRB (0.44) | F11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140329836-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140329836-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140329836-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-8624040-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-01-07 | — | — | US | disclosed |
| US-20110046157-A1 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-20110046157-A1 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-20110046157-A1 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-02-24 | — | — | US | disclosed |
| WO-2010151317-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329836-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC5, HDAC1 | HDAC6 1/4885BRD4 164/4885KDM1A 188/4885 |
| US-20110046157-A1 | Substituted hydroxamic acids and uses thereof | HDAC6, HDAC5, HDAC1 | HDAC6 1/4885BRD4 164/4885KDM1A 188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.